Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model - PubMed (original) (raw)
Affiliations
- PMID: 17487410
Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model
Zahari Raykov et al. Oncol Rep. 2007 Jun.
Abstract
Oncolytic viruses have emerged as a novel class of potent anticancer agents offering an improvement on chemo- and radiotherapy in terms of tumor targeting and reduction of side-effects. Among these agents, autonomous parvoviruses have attracted the attention of researchers for their ability to preferentially replicate in and kill transformed cells, and to suppress tumors in the absence of adverse reactions in various animal models. We have previously shown that lethally irradiated autologous tumor cells can support parvovirus H-1PV production and serve as carriers to deliver progeny H-1PV into the vicinity of lung metastases in a rat tumor model, resulting in H-1PV infection of and multiplication in metastatic cells. It is known that irradiated autologous (neoplastic) cells can also act as a therapeutic vaccine against the original tumor. Yet the ability of these cells to suppress metastases in the above model was found to be much increased as a result of their H-1PV infection. This prompted us to determine whether H-1PV boosted the tumor-suppressing capacity of the autologous vaccine by increasing its immunogenic potential and/or by making it a factory of oncolytic viruses able to reach and destroy the metastases. Both effects could be dissociated in the presence of neutralising antibodies which either prevent the progeny viruses from spreading to metastatic cells, or deplete the CD8 effector cells from the immune system. This strategy revealed that the H-1PV infection of tumor cells enhanced their ability to trigger an immune response for which uninfected tumor cells could be the targets, thereby amplifying and taking over from the direct viral oncolytic activity. This dual oncolytic/vaccinal effect of H-1PV holds out promises of clinical applications to cancer therapy.
Similar articles
- Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z. Rommelaere J, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7. Cytokine Growth Factor Rev. 2010. PMID: 20211577 Review. - Regression of glioma in rat models by intranasal application of parvovirus h-1.
Kiprianova I, Thomas N, Ayache A, Fischer M, Leuchs B, Klein M, Rommelaere J, Schlehofer JR. Kiprianova I, et al. Clin Cancer Res. 2011 Aug 15;17(16):5333-42. doi: 10.1158/1078-0432.CCR-10-3124. Epub 2011 Jun 29. Clin Cancer Res. 2011. PMID: 21715567 - Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR. Geletneky K, et al. J Biomed Biotechnol. 2010;2010:350748. doi: 10.1155/2010/350748. Epub 2010 Mar 7. J Biomed Biotechnol. 2010. PMID: 20224643 Free PMC article. - Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H, Dutuor A, Fu X, Zhang X. Li H, et al. J Gene Med. 2007 Mar;9(3):161-9. doi: 10.1002/jgm.1005. J Gene Med. 2007. PMID: 17266169 - Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K, Nüesch JP, Angelova A, Kiprianova I, Rommelaere J. Geletneky K, et al. Curr Opin Virol. 2015 Aug;13:17-24. doi: 10.1016/j.coviro.2015.03.008. Epub 2015 Apr 2. Curr Opin Virol. 2015. PMID: 25841215 Review.
Cited by
- Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Marchini A, et al. Front Immunol. 2019 Aug 7;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019. Front Immunol. 2019. PMID: 31440242 Free PMC article. Review. - Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A, Rommelaere J. Angelova A, et al. Viruses. 2019 May 4;11(5):415. doi: 10.3390/v11050415. Viruses. 2019. PMID: 31060205 Free PMC article. Review. - Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.
Marr M, D'Abramo A, Pittman N, Agbandje-McKenna M, Cotmore SF, Tattersall P. Marr M, et al. Viruses. 2018 Jan 30;10(2):54. doi: 10.3390/v10020054. Viruses. 2018. PMID: 29385689 Free PMC article. - Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C, Patel S, Mahalingam D. Fountzilas C, et al. Oncotarget. 2017 May 31;8(60):102617-102639. doi: 10.18632/oncotarget.18309. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254276 Free PMC article. Review. - Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL, Barf M, Geletneky K, Unterberg A, Rommelaere J. Angelova AL, et al. Viruses. 2017 Dec 15;9(12):382. doi: 10.3390/v9120382. Viruses. 2017. PMID: 29244745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials